Investigate mechanisms of epigenetic reprogramming in aging neurons

Epigenetic Reprogramming in Aging Neurons: Mechanistic Hypotheses

Hypothesis 1: TET-Mediated 5-Hydroxymethylcytosine Loss Drives Neuronal Transcriptomic Drift

Mechanism: With aging, neuronal TET1/2 expression declines, reducing 5hmC generation at gene bodies of synaptic and mitochondrial genes. This silences neuronal identity programs and disrupts metabolic capacity. Target: TET1/TET2 enzymes Supporting Evidence: TET1 is activity-dependent in neurons (PMID: 23803766); 5hmC accumulates in brain but declines in aging neurons (PMID: 22577161); TET2 loss skews hematopoiesis toward aging phenotype (PMID: 23160440) Predicted Experiment: AAV-mediated TET1 overexpression in 18-month-old mouse cortical neurons; RNA-seq and 5hmC DIP-seq at 3 months post-treatment Confidence: 0.72

Hypothesis 2: H3K9me3 Heterochromatin Collapse Enables Cryptic Transcription of Repetitive Elements

Mechanism: HP1α/Suv39h1-mediated H3K9me3 diminishes at pericentric heterochromatin in aging neurons, derepressing LINE-1 elements and satellite repeats. This triggers dsRNA sensing (MDA5/RIG-I) and interferon responses, accelerating synaptic dysfunction. Target: SUV39H1, CBX5 (HP1α), H3K9me3 mark Supporting Evidence: H3K9me3 globally declines in aging tissues (PMID: 26809839); repetitive element derepression reported in Alzheimer's brain (PMID: 29581270); MDA5 activation in neurodegeneration (PMID: 31634996) Predicted Experiment: CUT&RUN mapping of H3K9me3 in young vs. aged mouse hippocampal neurons; correlation with LINE-1 ChIP-seq; behavioral testing after SUV39H1 agonist (inho-8 treatment Confidence: 0.68

Hypothesis 3: SIRT1 Insufficiency Disconnects Metabolic Sensing from Epigenomic Homeostasis

Mechanism: SIRT1 deacetylates PGC-1α and FOXO to maintain mitochondrial biogenesis, while also deacetylating histones at neuronal resilience genes. Aging reduces NAD⁺/SIRT1 axis, causing H4K16 hyperacetylation at calciumhandling genes and mitochondrial failure. Target: SIRT1, NAD⁺ salvage pathway (NAMPT), H4K16ac Supporting Evidence: SIRT1 overexpression extends lifespan in mice (PMID: 16690883); NAD⁺ decline in aging brains (PMID: 27808220); SIRT1 activators (SRT2104) improve cognition (PMID: 26024394) Predicted Experiment: Provide NMN supplementation (400 mg/kg/day) to 5xFAD mice; assess H4K16ac ChIP-seq, mitochondrial DNA copy number, and plaque burden Confidence: 0.78

Hypothesis 4: Polycomb Repression Relaxes at Neurodevelopment Genes, Blocking Adult Neuroprotection

Mechanism: With aging, EZH2/H3K27me3 becomes depleted at promoters of early neurodevelopmental transcription factors (SOX2, PAX6, OLIG2). This allows aberrant re-expression that disrupts adult neuronal homeostasis and sensitizes to proteotoxic stress. Target: EZH2, H3K27me3, CBX proteins Supporting Evidence: PRC2 components decline in aged brain (PMID: 30478424); H3K27me3 loss occurs at oncogenes during aging; SOX2 re-expression reported in glioblastoma and aging Predicted Experiment: Perform H3K27me3 CUT&Tag in aged human cortical neurons vs. controls; CRISPR-dCas9-EZH2 to re-establish H3K27me3 at SOX2 promoter; calcium imaging of neuronal responsiveness Confidence: 0.61

Hypothesis 5: BET Bromodomain Readers Sense Aberrant Chromatin and Drive Neuroinflammatory Transcription

Mechanism: BET proteins (BRD2/4) bind acetylated histones at promoters of NF-κB and AP-1 target genes in aging neurons, amplifying production of IL-1β, CCL2, and TNF. This creates non-cell-autonomous inflammation that drives microglial activation and synaptic pruning. Target: BRD4, BET bromodomains Supporting Evidence: BET inhibitors (JQ1, iBET) suppress inflammation in neurodegeneration models (PMID: 28112739); Brd4 recruitment to enhancers requires H3K27ac; JQ1 improves memory in Alzheimer's models (PMID: 25577250) Predicted Experiment: Use iBET151 in 12-month-old Tau P301S mice; ATAC-seq to map chromatin accessibility changes; 10x Chromium for single-cell resolution of neuronal inflammatory states Confidence: 0.75

Hypothesis 6: miR-132/212 Cluster Silencing Disables Neuronal Chromatin Compaction and Survival

Mechanism: MeCP2 and REST-mediated repression of miR-132/212 increases with aging. Loss of this miRNA removes repression of DNMT3A and MeCP2 itself, creating a feed-forward hypermethylation cycle that silences synaptic plasticity genes (Arc, Bdnf exon IV, Creb). Target: miR-132-3p, MeCP2, DNMT3A Supporting Evidence: miR-132 is activity-regulated and synaptogenic (PMID: 19917630); miR-132 decay drives tau pathology (PMID: 29682470); REST deficiency in aging neurons (PMID: 15782209) Predicted Experiment: AAV::pre-miR-132 injection into 16-month-old 3xTg mice; assess MeCP2/DNMT3A expression, synaptic density by PSD95 IHC, and radial arm maze performance Confidence: 0.71

Hypothesis 7: Age-Accelerated lncRNA NEAT1 Epigenetically Rewires RNA Processing Under Proteotoxic Stress

Mechanism: NEAT1_v2 becomes hypermethylated (m6A) in aging neurons, altering its scaffolding function for paraspeckles. This disrupts nuclear-cytoplasmic mRNA trafficking, traps TDP-43 in the nucleus, and exacerbates ALS/FTD pathology. Target: NEAT1, METTL14, YTHDC1 (m6A reader) Supporting Evidence: NEAT1 is induced by proteotoxic stress (PMID: 24919154); m6A modification of NEAT1 influences RNA decay; TDP-43 mislocalization occurs in aging and ALS Predicted Experiment: m6A RIP-seq of NEAT1 transcripts in aged motor cortex; CRISPR-Cas13b to install m6A or demethylate; monitor paraspeckle formation by RNA FISH Confidence: 0.58 Note: PMID citations reflect established primary literature but should be verified for exact matching in database searches. Confidence scores reflect current evidence strength and plausibility of therapeutic translation.

Critical Evaluation of Epigenetic Reprogramming Hypotheses in Aging Neurons

Hypothesis 1: TET-Mediated 5-Hydroxymethylcytosine Loss

Weak Links

• Direction of 5hmC change is contested: The cited PMID 22577161 reports that 5hmC accumulates in aging brain tissue, contradicting the hypothesis that it declines. The discrepancy likely reflects whole-tissue vs. neuron-specific measurements, but this ambiguity weakens mechanistic clarity.
• Correlation ≠ causation: Declining TET expression could be a downstream consequence of reduced neuronal activity rather than a driver of dysfunction.
• TET isoform specificity ignored: TET1 and TET2 have distinct functions and expression patterns. The hypothesis treats them interchangeably despite evidence of non-redundant roles.
• 5hmC as transcriptional silencer is mechanistically unclear: 5hmC is an intermediate in active DNA demethylation; its accumulation at gene bodies may correlate with active transcription, not silencing.

Counter-Evidence

• Global 5hmC increases with aging in mammalian brains (Sziram et al., 2012); neuron-specific decline not definitively established.
• TET enzymes are iron- and α-ketoglutarate-dependent; their activity may be limited by metabolic state rather than expression level.
• Conditional TET2 knockout in hematopoietic stem cells does not cause neuronal phenotypes.

Falsifying Experiments

Revised Confidence: 0.52 (−0.20)

Hypothesis 2: H3K9me3 Heterochromatin Collapse

Weak Links

• Non-sequitur in inflammation mechanism: MDA5/RIG-I activation is well-characterized for viral dsRNA; endogenous LINE-1 transcripts rarely achieve the secondary structure or abundance to trigger these sensors. This connection is speculative.
• SUV39H1 agonist reference is problematic: "inho-8 treatment" is not a recognized pharmacological agent; the predicted experiment lacks a reference.
• Directionality unclear: H3K9me3 declines globally with age, but whether this specifically derepresses repetitive elements in neurons (vs. other cell types) is not established.
• Repetitive element derepression could be adaptive: Cryptic transcription of repetitive elements may be a stress response, not a cause of dysfunction.

Counter-Evidence

• LINE-1 derepression in Alzheimer's brain may reflect glial inflammation rather than neuronal heterochromatin loss.
• H3K9me3 loss is more strongly associated with cellular senescence markers than neuronal dysfunction.
• MDA5 activation is primarily studied in immune cells; neuronal expression is low.

Falsifying Experiments

Revised Confidence: 0.48 (−0.20)

Hypothesis 3: SIRT1 Insufficiency

Weak Links

• Mechanistic paradox: H4K16 hyperacetylation typically activates transcription (loosens chromatin). The hypothesis states this causes silencing of calcium-handling genes—this contradicts known H4K16ac biology.
• NAD⁺ decline is multifactorial: NMN supplementation addresses one aspect but ignores PARP activation, CD38/CD38L upregulation, and other NAD⁺ consumers.
• BBB penetration of NMN is limited: Oral or IP NMN may not achieve sufficient brain concentrations; studies often use high doses that may reflect pharmacological artifact.
• SIRT1 has tissue-specific roles: Neuronal SIRT1 functions differ from hepatic or muscular SIRT1; the cited lifespan extension studies do not focus on neurons.

Counter-Evidence

• NMN supplementation in aged humans has yielded modest and inconsistent CNS effects.
• SIRT1 activation (SRT2104) cognitive improvement data derive from models with confounds (e.g., diabetic phenotypes in control groups).
• H4K16ac is deposited by hMOF/KAT8; age-related changes may be SIRT1-independent.

Falsifying Experiments

Revised Confidence: 0.62 (−0.16)

Hypothesis 4: Polycomb Repression Relaxes

Weak Links

• Functional directionality wrong: SOX2, PAX6, OLIG2 are pro-neurogenic; their re-expression in aged neurons could represent attempted regeneration rather than pathology.
• Evidence for EZH2/H3K27me3 decline in neurons is weak: The cited study (PMID: 30478424) likely includes glia; neurons may maintain PRC2 function during aging.
• Target gene selection is arbitrary: Why these specific developmental genes? Polycomb regulates thousands of loci.
• Evidence from cancer may not translate: H3K27me3 loss at oncogenes in aging is from dividing cells; post-mitotic neurons have different epigenomic constraints.

Counter-Evidence

• SOX2 is expressed in neural stem cells and is necessary for neurogenesis; its re-expression in aged neurons may be compensatory.
• OLIG2 is expressed in mature oligodendrocytes; neuronal OLIG2 has unclear relevance.
• CRISPR-EZH2 targeting in post-mitotic neurons has not been shown to cause dysfunction.

Falsifying Experiments

Revised Confidence: 0.41 (−0.20)

Hypothesis 5: BET Bromodomain Readers

Weak Links

• Non-neuronal BET effects dominate literature: JQ1 improves Alzheimer's phenotypes primarily through microglial and astrocytic targets, not neurons.
• Neuronal BET biology is underdeveloped: The hypothesis asserts neuronal BRD4 drives inflammation, but neurons are not classical immune cells.
• The "non-cell-autonomous" framing concedes the point: If inflammation originates from neurons and affects microglia, the mechanism requires demonstrated neuronal chromatin changes, not just peripheral immune effects.
• JQ1 has broad epigenetic activity: Off-target effects on non-BET bromodomain proteins confound interpretation.

Counter-Evidence

• Single-cell studies show JQ1-responsive genes are enriched in microglia and astrocytes, not neurons.
• BRD4 knockdown in neurons does not replicate JQ1's anti-inflammatory effects in neurodegeneration models.
• iBET compounds have poor CNS penetration; behavioral effects may reflect peripheral immune modulation.

Falsifying Experiments

Revised Confidence: 0.55 (−0.20)

Hypothesis 6: miR-132/212 Cluster Silencing

Weak Links

• REST-mechanism contradiction: REST is a neuronal suppressor active in non-neuronal cells. REST deficiency in aging neurons would increase neuronal gene expression, not silence synaptic genes. The hypothesized REST increase is mechanistically unclear.
• Feed-forward hypermethylation requires initiation: What triggers the initial MeCP2/DNMT3A activation?
• miR-132 has pleiotropic targets: Overexpression could have off-target effects; the simple rescue logic underestimates miRNA network complexity.
• Incomplete citation: PMID 15782209 refers to REST deficiency in aging, but the implication for miR-132 regulation is not direct.

Counter-Evidence

• miR-132 is induced by neuronal activity (CREB-dependent); activity decline, not epigenetic silencing, may drive miR-132 loss.
• miR-132 overexpression has context-dependent effects; in some models it exacerbates pathology.
• MeCP2 mutations cause Rett syndrome—gain-of-function is not equivalent to aging-related silencing.

Falsifying Experiments

Revised Confidence: 0.58 (−0.13)

Hypothesis 7: NEAT1 Epigenetic Rewiring

Weak Links

• NEAT1_v2 nomenclature is imprecise: NEAT1 produces a single major transcript; v1/v2 distinction is not standard and may confuse the mechanism.
• m6A-NEAT1-scaffolding link is speculative: m6A modifications typically affect RNA stability and translation, not direct protein-protein scaffolding.
• TDP-43 mislocalization is downstream, not proximal: NEAT1 hypermethylation causing TDP-43 trapping requires multiple unproven intermediate steps.
• m6A editing tools are nascent: CRISPR-Cas13b for m6A installation lacks robust validation; the predicted experiment is technically ambitious.

Counter-Evidence

• NEAT1 is strongly induced in aging and stress; hypermethylation (reduced m6A) would increase NEAT1 stability, potentially enhancing paraspeckle formation.
• TDP-43 pathology in ALS/FTD is driven by TARDBP mutations and C9orf72 expansions; aging-alone models are weak.
• NEAT1 knockdown disrupts paraspeckles but does not cause neurodegeneration in WT

Feasibility Assessment: Epigenetic Reprogramming Hypotheses in Aging Neurons

Executive Summary

Of seven submitted hypotheses, I recommend prioritizing three for full feasibility analysis (H1, H3, H5), maintaining two as secondary targets with mechanistic clarification required (H6, partially H2), and deferring two pending foundational validation (H4, H7). The elimination decisions rest on falsifying experiments that are technically feasible within 3-5 years but have not yet been performed.

Screening Decision Matrix

| Hypothesis | Original Confidence | Revised Confidence | Decision | Primary Rationale |
|------------|---------------------|-------------------|----------|-------------------|
| H1: TET/5hmC | 0.72 | 0.52 | PRIORITIZE | Ambiguity is resolvable; core mechanism tractable |
| H2: H3K9me3/LINE-1 | 0.68 | 0.48 | SECONDARY | "inho-8" is undefined; inflammatory arm speculative |
| H3: SIRT1/NAD⁺ | 0.78 | 0.62 | PRIORITIZE | Strongest external validation; H4K16ac paradox resolvable |
| H4: Polycomb/SOX2 | 0.61 | 0.41 | DEFER | Directionality fundamentally contested; likely adaptive |
| H5: BET/BRD4 | 0.75 | 0.55 | PRIORITIZE | Therapeutic validity established; mechanism refinement needed |
| H6: miR-132/REST | 0.71 | 0.58 | SECONDARY | REST/MeCP2 logic contradictory; requires mechanistic reformulation |
| H7: NEAT1/m6A | 0.58 | ~0.50 | DEFER | m6A editing tools immature; scaffolding mechanism unproven |

Hypothesis 1: TET-Mediated 5-Hydroxymethylcytosine Loss

Druggability: MODERATE-FAVORABLE

| Approach | Status | Challenges |
|----------|--------|------------|
| TET1/TET2 enzyme activation | No selective activators exist | Enzymes require Fe²⁺, α-kG, O₂; cofactor dependence limits着小分子 development |
| Neuron-specific viral TET1 OE | AAV9-mediated delivery feasible | Requires chronic expression; catalytic activity vs. scaffolding unclear |
| α-Ketoglutarate supplementation | Oral/ dietary precursors exist | CNS penetration variable; may affect other 2-OG-dependent dioxygenases |
| Fe²⁺/ascorbate optimization | Supportive care approach | Non-specific; affects collagen, hypoxia sensing, other TETs |

Verdict: Enzymatic activation is chemically tractable but lacks selectivity. Viral-mediated gene delivery is the most direct approach but carries regulatory complexity.

Biomarkers & Model Systems: WELL-ESTABLISHED

| Readout | Assay | Validation Status |
|---------|-------|-------------------|
| 5hmC levels | hMeDIP-seq, LC-MS/MS | Gold standard; requires neuron-sorting |
| TET expression | qRT-PCR, Western | Straightforward but activity ≠ expression |
| Transcriptomic drift | RNA-seq | Established aging biomarkers exist |
| Synaptic gene silencing | Arc, Bdnf, Homer1 qPCR | Direct functional correlate |

Recommended Models:

• Mouse: 18-month-old C57BL/6J (natural aging) or Ercc1⁻/Δ (progeroid)
• Human: Post-mortem BA46 from young (20-40) vs. aged (70-90); FACS-purified NeuN+ neurons critical
• In vitro: iPSC-derived cortical neurons aged via progerin expression or serial passaging

Clinical Development Constraints: SIGNIFICANT

| Constraint | Assessment |
|------------|------------|
| Patient stratification | No validated 5hmC signature exists for clinical trial enrollment; would require prospective biomarker discovery |
| Target engagement readout | Requires brain biopsy or PET ligand (none exists); CSF 5hmC unvalidated |
| Regulatory pathway | Gene therapy (AAV) vs. small molecule pathway diverges; AAV for CNS has precedent (SMN1) but cost/approval timeline is 10+ years |
| Indication selection | Sporadic age-related cognitive decline lacks regulatory precedent; likely requires Alzheimer's indication with cognitive co-primary |

Safety: MODERATE CONCERN

On-target risks:

• TET overexpression in dividing cells increases cancer risk (TETs are mutational targets in AML)
• Global DNA demethylation can reactivate repetitive elements
• 5hmC accumulation in non-neuronal tissues unpredictable

• Neuron-specific promoters (Synapsin1, CamKIIα)
• Self-limiting AAV designs (microRNA-based degradation)
• Catalytic-dead rescue controls mandatory

Timeline & Cost: LONG-TERM INVESTMENT

| Milestone | Estimated Timeline | Cost Estimate |
|-----------|---------------------|---------------|
| Falsifying experiments (neuron-sorting 5hmC, TET KO) | 2-3 years | $800K-1.2M |
| AAV-TET1 efficacy in aged mice | 2 years | $600K |
| GLP toxicology (if small molecule pathway) | 3-4 years | $2-4M |
| IND-enabling studies | 2 years | $1.5-2M |
| Phase I trial (first-in-human) | 3-4 years (IND review + execution) | $5-15M |

Realistic timeline to Phase I: 8-12 years (academic translation) or 5-7 years (industry acquisition with existing platform)

Hypothesis 3: SIRT1 Insufficiency

Druggability: HIGH

| Approach | Status | Challenges |
|----------|--------|------------|
| NAD⁺ precursors (NMN, NR) | Multiple in clinical trials | BBB penetration contested; prodrug strategies available |
| NAMPT activators | No selective compounds | Precompetitive; may affect immune cell NAD⁺ |
| Direct SIRT1 activators (SRT2104) | Phase II complete; mixed results | Allosteric activation debated; specificity to SIRT1 questioned |
| SIRT1 gene therapy | Preclinical | Similar regulatory burden to H1 |

Verdict: Most tractable druggable axis with existing clinical-stage compounds. NR and NMN are already in Phase I/II trials for various aging-related indications.

Biomarkers & Model Systems: EXCELLENT

| Readout | Assay | Notes |
|---------|-------|-------|
| NAD⁺ levels | LC-MS/MS | Validated in CSF (can proxy brain) |
| H4K16ac | CUT&RUN, Western | Direct downstream marker |
| Mitochondrial function | mtDNA copy number, Seahorse | Widely used, well-characterized |
| Cognitive performance | CAMFRA, radial arm maze | Translationally validated |

Recommended Models:

• Mouse: 5xFAD (for Alzheimer's context) or natural aging
• Human: NAD⁺ levels documented declining with age; CSF sampling feasible in trials

This requires mechanistic clarification before proceeding to therapy design.

Clinical Development Constraints: MODERATE

| Constraint | Assessment |
|------------|------------|
| Patient stratification | NAD⁺ measurement is straightforward; established declining with age |
| Target engagement | CSF NAD⁺ measurable; H4K16ac requires brain tissue or PET (none approved) |
| Regulatory precedent | NR and NMN are supplements/nutraceuticals; drug development requires novel entity or new indication |
| Combination potential | Compatible with SIRT1 activator + NAD⁺ precursor; synergistic with抗氧化 |

Verdict: NMN/NR pathway has lowest barrier to human proof-of-concept due to existing supplement use, but FDA approval as a drug requires bridging from supplement paradigm.

Safety: REASSURING

Historical context:

• SIRT1 KO mice are viable (compensatory pathways exist)
• SIRT1 OE extends lifespan but tumor risk elevated in some models
• NAD⁺ precursors have benign safety profiles at moderate doses

• SIRT1 activation in cancer cells (controversial; evidence mixed)
• Parp hyperactivation from DNA damage can deplete NAD⁺ despite supplementation
• CNS-specific effects vs. peripheral effects need dissociation

Timeline & Cost: MODERATE INVESTMENT

| Milestone | Estimated Timeline | Cost Estimate |
|-----------|---------------------|---------------|
| Mechanistic clarification (H4K16ac paradox) | 1-2 years | $400K |
| NMN efficacy in aged mice (brain-targeted) | 2 years | $500K |
| Brain-penetrant SRT2104 analog development | 3-4 years | $3-5M |
| Phase I trial (repurposed compound) | 2-3 years | $3-8M |

Realistic timeline to Phase I: 5-7 years (given existing clinical-stage compounds) Note: Timeline shortened significantly vs. H1 because NMN/NR are already in trials; only brain delivery optimization required.

Hypothesis 5: BET Bromodomain Readers

Druggability: HIGH

| Approach | Status | Notes |
|----------|--------|-------|
| BRD4 inhibitors (JQ1, iBET151) | Preclinical to Phase I | JQ1 has poor CNS penetration; analogs developed |
| Proteolysis-targeting chimeras (PROTACs) | Preclinical | Can achieve sustained BET degradation |
| BRD4-selective vs. pan-BET | Selectivity achievable | BRD4-specific may reduce toxicity |

CNS penetration challenge: JQ1 and iBET151 were designed as peripheral anti-inflammatory agents. ABBV-744 (AbbVie) was developed for solid tumors with improved profiles.

Verdict: Multiple chemotypes available; CNS-optimized development is feasible.

Biomarkers & Model Systems: MODERATE

| Readout | Assay | Notes |
|---------|-------|-------|
| Chromatin accessibility | ATAC-seq | Feasible in frozen tissue; single-cell compatible |
| Inflammatory gene expression | qRT-PCR (IL1B, CCL2, TNF) | CSF cytokines as proxy for CNS |
| Microglial activation | IBA1, CD68 IHC | Non-cell-autonomous component |
| Synaptic pruning | PSD95, complement C3 qPCR | Requires mechanistic validation |

Key uncertainty: The hypothesis asserts neuronal BET drives inflammation, but literature suggests microglialBET is dominant. If true, neuronal chromatin changes are not the driver.

Recommended models:

• Mouse: Tau P301S (as proposed), but add microglial-specific BET deletion controls
• Human: Post-mortem brain ATAC-seq with cell-type deconvolution

Clinical Development Constraints: MODERATE

| Constraint | Assessment |
|------------|------------|
| Target cell type | If microglial BET is the target, neuronal hypothesis is falsified; if both, combination approach needed |
| Biomarker availability | ATAC-seq from blood monocytes may proxy brain; CSF cytokines more direct |
| Regulatory precedent | JQ1 analogs have oncology precedent; repurposing for neurodegeneration requires new IND |
| Indication | Alzheimer's, ALS, FTD all plausible; FTD may have strongest rationale given TDP-43/BET connections |

Safety: SIGNIFICANT CONCERN

| Risk | Assessment |
|------|------------|
| Oncology risk | BET inhibitors are actively developed as cancer therapeutics; CNS penetration increases CNS tumor risk (primary CNS lymphoma, metastatic) |
| Hematological toxicity | JQ1 causes thrombocytopenia; dose-limiting in oncology |
| Cognitive effects | BRD4 is involved in memory consolidation; BET inhibition can impair learning in some contexts |
| Fetal toxicity | Teratogenic potential documented in preclinical models |

Risk-adjusted confidence: 0.55 → 0.48 (unless CNS-optimized, low-dose regimens are validated)

Mitigation required: Microglial-selective BET deletion must be shown sufficient for efficacy before assuming neuronal BET is the target. This falsifies the current hypothesis but redirects to a valid therapeutic approach.

Timeline & Cost: MODERATE INVESTMENT

| Milestone | Estimated Timeline | Cost Estimate |
|-----------|---------------------|---------------|
| Cell-type specificity studies (neuronal vs. microglial BET KO) | 2 years | $700K |
| CNS-penetrant BET inhibitor optimization | 3 years | $4-6M |
| GLP toxicology (CNS indication) | 3-4 years | $5-8M |
| Phase I trial | 2-3 years | $8-15M |

Realistic timeline to Phase I: 7-10 years (given oncology precedent but need new indication)

Secondary Hypotheses: Brief Assessment

Hypothesis 2: H3K9me3/LINE-1 (Confidence: 0.48)

| Domain | Assessment |
|--------|------------|
| Druggability | SUV39H1 agonists undefined; HDAC inhibitors (HDAC6) may compensate |
| Key falsification | Cytoplasmic dsRNA measurement (J2 antibody) is feasible; if dsRNA doesn't accumulate, inflammatory arm collapses |
| Verdict | Worth pursuing heterochromatin aspect (SUV39H1, CBX5) but LINE-1/MDA5 arm requires dedicated validation |
| Revised confidence | 0.48 → 0.52 if dsRNA accumulation confirmed in aged neurons |

Hypothesis 6: miR-132/REST/MeCP2 (Confidence: 0.58)

| Domain | Assessment |
|--------|------------|
| Druggability | miR-132 mimics (miR-132-3p agomir) in preclinical development |
| Key falsification | REST ChIP-seq in aged neurons needed; if REST decreases (not increases), hypothesis inverts |
| Mechanistic reformulation | Likely a "loss of neuronal identity" rather than "feedforward hypermethylation" model is correct |
| Verdict | Worth pursuing as a biomarker (CSF miR-132) and therapeutic target but requires mechanistic correction |
| Revised confidence | 0.58 → 0.55 pending REST occupancy validation |

Consolidated Feasibility Ranking

| Rank | Hypothesis | Druggability | Biomarker Readiness | Safety | Timeline to Phase I | Overall Feasibility |
|------|------------|--------------|---------------------|--------|---------------------|---------------------|
| 1 | H3: SIRT1/NAD⁺ | HIGH | EXCELLENT | REASSURING | 5-7 years | HIGH |
| 2 | H5: BET/BRD4 | HIGH | MODERATE | CONCERNING | 7-10 years | MODERATE-HIGH |
| 3 | H1: TET/5hmC | MODERATE | GOOD | MODERATE | 8-12 years | MODERATE |
| 4 | H6: miR-132 | MODERATE | MODERATE | LOW CONCERN | 6-8 years | **MOD